Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
This grant supports research on preventing and treating fetal alcohol spectrum disorders (FASD) through a phased approach, with a focus on clinical trials.
Funder: National Institutes of Health
Due Dates: November 17, 2026 (Resubmissions; closing date)
Funding Amounts: R61: up to $350,000 direct costs over 2 years; R33: up to $500,000 direct costs annually for up to 3 years
Summary: Supports phased research on preventing prenatal alcohol exposure and developing interventions for fetal alcohol spectrum disorders throughout the lifespan.
Key Information: R33 support requires successful R61 milestones and clinical translation; animal-only and HIV/AIDS research are not responsive.
Description
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) supports biomedical, behavioral, and social science research to prevent fetal alcohol spectrum disorders (FASD) and improve outcomes for affected individuals throughout the lifespan. Research may address reducing alcohol use during pregnancy, mitigating physical and neurobehavioral deficits, strengthening caregiver or educational approaches, and improving identification and access to care. Clinical trials are optional but receive highest priority.
The R61/R33 Exploratory/Developmental Phased Award begins with pilot studies, secondary data analysis, technical development, or proof-of-principle research. The R33 phase expands supported hypotheses through further development, application, and evaluation of clinical utility, laying a foundation for larger efficacy studies. Applications must connect proposed prevention or intervention components to their hypothesized mechanisms and targeted outcomes.
